The Alzheimer's Drug Discovery Foundation
@theaddf.bsky.social
The Alzheimer's Drug Discovery Foundation's mission is to rapidly accelerate the discovery and development of drugs to prevent, treat, and cure Alzheimer's.
Topline results from the Evoke & Evoke+ Phase 3 trials show new insights despite missed endpoints. ADDF’s early support helps advance research, and the data will guide future combination therapy strategies for #Alzheimer’s. bit.ly/4rgojdS
November 24, 2025 at 4:58 PM
Topline results from the Evoke & Evoke+ Phase 3 trials show new insights despite missed endpoints. ADDF’s early support helps advance research, and the data will guide future combination therapy strategies for #Alzheimer’s. bit.ly/4rgojdS
Mark Roithmayr, ADDF CEO, shares his journey in #philanthropy, reflecting on the lessons, people, & moments that shaped his leadership and impact on Team Powdered Donut. Tune in for a conversation full of heart and purpose-driven leadership, driving real-world change. bit.ly/3M9s5FG
November 20, 2025 at 5:11 PM
Mark Roithmayr, ADDF CEO, shares his journey in #philanthropy, reflecting on the lessons, people, & moments that shaped his leadership and impact on Team Powdered Donut. Tune in for a conversation full of heart and purpose-driven leadership, driving real-world change. bit.ly/3M9s5FG
The ADDF is proud to partner with JPAD on a landmark issue on combination therapies. Just as they transformed cancer care, combination therapies are poised to do the same for #Alzheimer’s, providing a roadmap for advancing critical research.
bit.ly/3XqcdRA
bit.ly/3XqcdRA
November 13, 2025 at 4:23 PM
The ADDF is proud to partner with JPAD on a landmark issue on combination therapies. Just as they transformed cancer care, combination therapies are poised to do the same for #Alzheimer’s, providing a roadmap for advancing critical research.
bit.ly/3XqcdRA
bit.ly/3XqcdRA
A new CBS Sunday segment spotlights how partnerships are driving optimism in Alzheimer’s research. @billgates.bsky.social highlights how breakthroughs in blood tests, biomarkers & AI, spearheaded by the Diagnostics Accelerator, are reshaping the field. www.cbsnews.com/news/promisi...
Promising clinical trials in Alzheimer's prevention
Washington University Medicine in St. Louis is conducting important research into treating early-onset Alzheimer's before symptoms arise.
www.cbsnews.com
November 10, 2025 at 8:29 PM
A new CBS Sunday segment spotlights how partnerships are driving optimism in Alzheimer’s research. @billgates.bsky.social highlights how breakthroughs in blood tests, biomarkers & AI, spearheaded by the Diagnostics Accelerator, are reshaping the field. www.cbsnews.com/news/promisi...
The Annual Fall Symposium & Luncheon celebrated 27 years of vision from Leonard & Ronald Lauder, inspiring science & honorees! Phebe Farrow Port received the Charles Evans Award and Martha & Peter Webster received the Visionary Partner Award. bit.ly/47letQ0
November 3, 2025 at 11:08 PM
The Annual Fall Symposium & Luncheon celebrated 27 years of vision from Leonard & Ronald Lauder, inspiring science & honorees! Phebe Farrow Port received the Charles Evans Award and Martha & Peter Webster received the Visionary Partner Award. bit.ly/47letQ0
The ADDF celebrates the opening of the Center for Aging Well at Yale Nursing, led by Dr. Miia Kivipelto. Her pioneering work in brain health and aging continues to shape the future of precision prevention and #Alzheimer’s care.
bit.ly/4hFhUVe
bit.ly/4hFhUVe
October 31, 2025 at 1:41 PM
The ADDF celebrates the opening of the Center for Aging Well at Yale Nursing, led by Dr. Miia Kivipelto. Her pioneering work in brain health and aging continues to shape the future of precision prevention and #Alzheimer’s care.
bit.ly/4hFhUVe
bit.ly/4hFhUVe
In a special Power of Ideas series, Howard Fillit highlighted the pivotal inflection point #Alzheimer’s science has reached in recent years. The ADDF is driving #breakthroughs through bold partnerships and cross-sector #collaboration. @milkeninstitute.org
milkeninstitute.org/content-hub/...
milkeninstitute.org/content-hub/...
October 29, 2025 at 7:26 PM
In a special Power of Ideas series, Howard Fillit highlighted the pivotal inflection point #Alzheimer’s science has reached in recent years. The ADDF is driving #breakthroughs through bold partnerships and cross-sector #collaboration. @milkeninstitute.org
milkeninstitute.org/content-hub/...
milkeninstitute.org/content-hub/...
Can GLP-1s also combat Alzheimer’s? Novo Nordisk’s EVOKE trial results will be presented at CTAD, building on ADDF-funded research by Dr. Paul Edison on liraglutide. Repurposed drugs & precision medicine could redefine how we treat #Alzheimer’s. on.ft.com/3J1HpTU
Novo Nordisk’s ‘lottery ticket’: can obesity drugs help treat Alzheimer’s?
Results are due soon from two studies using semaglutide to treat thousands of people with the disease
on.ft.com
October 16, 2025 at 8:56 PM
Can GLP-1s also combat Alzheimer’s? Novo Nordisk’s EVOKE trial results will be presented at CTAD, building on ADDF-funded research by Dr. Paul Edison on liraglutide. Repurposed drugs & precision medicine could redefine how we treat #Alzheimer’s. on.ft.com/3J1HpTU
Reposted by The Alzheimer's Drug Discovery Foundation
The World Dementia Council is hosting a virtual event on “Lessons from innovators: biomarkers.” Supported by @theaddf.bsky.social, this dialogue will explore rapid advances & key challenges in developing new dementia diagnostics. More here: bit.ly/4kUT4Re
October 14, 2025 at 2:50 PM
The World Dementia Council is hosting a virtual event on “Lessons from innovators: biomarkers.” Supported by @theaddf.bsky.social, this dialogue will explore rapid advances & key challenges in developing new dementia diagnostics. More here: bit.ly/4kUT4Re
Alzheimer’s care is evolving. The FDA clearance of Roche and @elilillyandcompany.bsky.social Elecsys pTau181 blood test marks a major step toward accessible, scalable diagnostics that bring detection into everyday clinical care. @cnn.com
FDA clears blood test to help rule out Alzheimer’s disease in people showing symptoms | CNN
The US Food and Drug Administration has given clearance to another blood test to help assess Alzheimer’s disease and other causes of cognitive decline, providing a broader understanding of when the di...
cnn.it
October 14, 2025 at 8:57 PM
Alzheimer’s care is evolving. The FDA clearance of Roche and @elilillyandcompany.bsky.social Elecsys pTau181 blood test marks a major step toward accessible, scalable diagnostics that bring detection into everyday clinical care. @cnn.com
We’re proud to celebrate Eisai and Biogen for Leqembi Iqlik being named one of TIME's Best Inventions of 2025. This marks incredible innovation in Alzheimer’s care, paving the way for faster & simpler delivery that can be self-administered at home like GLP-1s. bit.ly/4q9P976
Eisai and Biogen Leqembi Iqlik: The Best Inventions of 2025
Find out why Eisai and Biogen Leqembi Iqlik is on TIME's list of 2025's best inventions.
bit.ly
October 10, 2025 at 3:19 PM
We’re proud to celebrate Eisai and Biogen for Leqembi Iqlik being named one of TIME's Best Inventions of 2025. This marks incredible innovation in Alzheimer’s care, paving the way for faster & simpler delivery that can be self-administered at home like GLP-1s. bit.ly/4q9P976
Congratulations to our friend and partner Anne White, who has been named one of Endpoints News’ Women in Biopharma 2025. Anne’s impact and leadership at @elilillyandcompany.bsky.social from advancing oncology to Alzheimer’s breakthroughs continues to transform the field.
bit.ly/3INh5wG
bit.ly/3INh5wG
Meet 20 women reshaping biopharma, from early discovery to patient advocacy
A project highlighting women in biopharma has grown since 2019, now honoring over 140 women who've shaped the industry through work on rare diseases, IPOs, AI drug discovery and patient advocacy. Desp...
endpoints.news
October 8, 2025 at 4:48 PM
Congratulations to our friend and partner Anne White, who has been named one of Endpoints News’ Women in Biopharma 2025. Anne’s impact and leadership at @elilillyandcompany.bsky.social from advancing oncology to Alzheimer’s breakthroughs continues to transform the field.
bit.ly/3INh5wG
bit.ly/3INh5wG
The conversation around Alzheimer’s care is shifting. Dr. Jason Karlawish explores how advances in disease-modifying therapies and novel diagnostics are transforming society at large—a future defined by combination therapy and precision medicine. bit.ly/3KD9IIx
The way we talk about dementia is about to change completely
“The more we talk, debate, even sometimes argue, the more we can live well with a mind altered by these progressive, disabling brain diseases,” Jason Karlawish writes.
bit.ly
October 7, 2025 at 2:07 PM
The conversation around Alzheimer’s care is shifting. Dr. Jason Karlawish explores how advances in disease-modifying therapies and novel diagnostics are transforming society at large—a future defined by combination therapy and precision medicine. bit.ly/3KD9IIx
Today, our partners C2N Diagnostics submitted the #PrecivityAD2 blood test to the #FDA for approval, enabling earlier diagnosis and intervention for Alzheimer's treatment, a core tenet of the ADDF's DxA. The next frontier is precision medicine. bit.ly/46Lw4yV
October 1, 2025 at 5:02 PM
Today, our partners C2N Diagnostics submitted the #PrecivityAD2 blood test to the #FDA for approval, enabling earlier diagnosis and intervention for Alzheimer's treatment, a core tenet of the ADDF's DxA. The next frontier is precision medicine. bit.ly/46Lw4yV
The ADDF’s DxA announced two milestones: the release of #SpeechDx’s first data tranche & a new partnership with
Callyope. This gold-standard dataset will power a new generation of #AI tools to detect, diagnose, monitor, and even treat Alzheimer’s.
bit.ly/4ohctOz
Callyope. This gold-standard dataset will power a new generation of #AI tools to detect, diagnose, monitor, and even treat Alzheimer’s.
bit.ly/4ohctOz
September 30, 2025 at 1:14 PM
The ADDF’s DxA announced two milestones: the release of #SpeechDx’s first data tranche & a new partnership with
Callyope. This gold-standard dataset will power a new generation of #AI tools to detect, diagnose, monitor, and even treat Alzheimer’s.
bit.ly/4ohctOz
Callyope. This gold-standard dataset will power a new generation of #AI tools to detect, diagnose, monitor, and even treat Alzheimer’s.
bit.ly/4ohctOz
Missed our latest webinar? Tune in to an extraordinary conversation with the ADDF’s scientific leaders, Aaron Burstein, PharmD, and Melissa Lee, PhD, as they discuss the cutting-edge #Alzheimer’s research in 2025, fueled by the ADDF’s bold vision.
www.youtube.com/watch?v=I_XO...
www.youtube.com/watch?v=I_XO...
Meet the Minds Behind the Mission: A Q&A with ADDF Scientists
YouTube video by Alzheimer's Drug Discovery Foundation
www.youtube.com
September 29, 2025 at 6:18 PM
Missed our latest webinar? Tune in to an extraordinary conversation with the ADDF’s scientific leaders, Aaron Burstein, PharmD, and Melissa Lee, PhD, as they discuss the cutting-edge #Alzheimer’s research in 2025, fueled by the ADDF’s bold vision.
www.youtube.com/watch?v=I_XO...
www.youtube.com/watch?v=I_XO...
The European Commission has authorized #Kisunla, marking a new era in #Alzheimer's treatment and accelerating global innovation. This milestone expands access for patients and families, enabling early detection and treatments that help slow decline. @elilillyandcompany.bsky.social
bit.ly/46mYY9M
bit.ly/46mYY9M
September 26, 2025 at 4:22 PM
The European Commission has authorized #Kisunla, marking a new era in #Alzheimer's treatment and accelerating global innovation. This milestone expands access for patients and families, enabling early detection and treatments that help slow decline. @elilillyandcompany.bsky.social
bit.ly/46mYY9M
bit.ly/46mYY9M
Alzheimer’s is undergoing a diagnostic revolution. A new series from The Lancet explores how advances in biomarkers are transforming diagnosis, enabling more equitable and affordable access to treatment, which speaks to the DxA’s mission.
bit.ly/4pFkVID
bit.ly/4pFkVID
New landscape of the diagnosis of Alzheimer's disease
Alzheimer's disease involves a drastic departure from the cognitive, functional, and
behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent
cause of disability to individu...
bit.ly
September 24, 2025 at 9:14 PM
Alzheimer’s is undergoing a diagnostic revolution. A new series from The Lancet explores how advances in biomarkers are transforming diagnosis, enabling more equitable and affordable access to treatment, which speaks to the DxA’s mission.
bit.ly/4pFkVID
bit.ly/4pFkVID
A new era of Alzheimer's treatment is here. Dr. Fillit shares with
@sciam.bsky.social that the future lies in precision combination therapies, like in cancer. The path forward will combine anti-amyloid and tau therapies with novel treatments that target the biology of aging, such as inflammation.
@sciam.bsky.social that the future lies in precision combination therapies, like in cancer. The path forward will combine anti-amyloid and tau therapies with novel treatments that target the biology of aging, such as inflammation.
Doctors Are Torn over Controversial New Alzheimer’s Treatments. Here’s Why
New Alzheimer’s drugs known as anti-amyloid therapies may slow disease progression—but they also carry serious risks, including brain bleeds and strokelike symptoms
www.scientificamerican.com
September 23, 2025 at 1:37 PM
A new era of Alzheimer's treatment is here. Dr. Fillit shares with
@sciam.bsky.social that the future lies in precision combination therapies, like in cancer. The path forward will combine anti-amyloid and tau therapies with novel treatments that target the biology of aging, such as inflammation.
@sciam.bsky.social that the future lies in precision combination therapies, like in cancer. The path forward will combine anti-amyloid and tau therapies with novel treatments that target the biology of aging, such as inflammation.
With advances in #AI-powered tools, Melissa Lee, PhD, highlights the ADDF’s Diagnostics Accelerator vision: a future where blood tests, speech samples, and digital tools enable early detection and personalized care for #Alzheimer’s.
www.linkedin.com/pulse/what-w...
www.linkedin.com/pulse/what-w...
What if we could stop Alzheimer’s before it starts?
Imagine knowing years in advance who will develop Alzheimer’s and when. Imagine being able to use that time to act – deploying targeted drugs and lifestyle interventions to prevent the disease from ev...
www.linkedin.com
September 16, 2025 at 5:00 PM
With advances in #AI-powered tools, Melissa Lee, PhD, highlights the ADDF’s Diagnostics Accelerator vision: a future where blood tests, speech samples, and digital tools enable early detection and personalized care for #Alzheimer’s.
www.linkedin.com/pulse/what-w...
www.linkedin.com/pulse/what-w...
On the latest episode of Managed Care Cast, Dr. Fillit and Dr. Anthony Sireci, @elilillyandcompany.bsky.social, discuss a transformative milestone in Alzheimer’s care: the first-ever FDA clearance for a blood test, the Lumipulse plasma assay. bit.ly/47GLnv8
Navigating the Alzheimer Disease Blood Test Revolution
A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.
bit.ly
September 12, 2025 at 5:40 PM
On the latest episode of Managed Care Cast, Dr. Fillit and Dr. Anthony Sireci, @elilillyandcompany.bsky.social, discuss a transformative milestone in Alzheimer’s care: the first-ever FDA clearance for a blood test, the Lumipulse plasma assay. bit.ly/47GLnv8
Reposted by The Alzheimer's Drug Discovery Foundation
Alzheimer’s Disease: Diagnosis & Treatment: Blood tests that show biomarkers for Alzheimer’s disease can delay onset of symptoms.
.
Learn more here: bbrfoundation.org/healthy-mind...
.
@theaddf.bsky.social @pbs.org #mentalhealth
.
Learn more here: bbrfoundation.org/healthy-mind...
.
@theaddf.bsky.social @pbs.org #mentalhealth
September 10, 2025 at 3:59 PM
Alzheimer’s Disease: Diagnosis & Treatment: Blood tests that show biomarkers for Alzheimer’s disease can delay onset of symptoms.
.
Learn more here: bbrfoundation.org/healthy-mind...
.
@theaddf.bsky.social @pbs.org #mentalhealth
.
Learn more here: bbrfoundation.org/healthy-mind...
.
@theaddf.bsky.social @pbs.org #mentalhealth
#GLP-1s have the potential to redefine #Alzheimer's treatment. @a_hfillit shared with #Bloomberg that #semaglutide could become “one of the first anti-aging drugs,” bringing Alzheimer’s care closer to combination therapies & precision medicine, like in cancer. bloom.bg/4nipzdO
Novo Has High Hopes That Ozempic Pill Can Also Fight Dementia
From obesity and diabetes to heart and liver disease, the applications for GLP-1 drugs have multiplied since Ozempic arrived on the scene seven years ago. Now, Novo is testing their effect on Alzheime...
bloom.bg
September 4, 2025 at 4:15 PM
#GLP-1s have the potential to redefine #Alzheimer's treatment. @a_hfillit shared with #Bloomberg that #semaglutide could become “one of the first anti-aging drugs,” bringing Alzheimer’s care closer to combination therapies & precision medicine, like in cancer. bloom.bg/4nipzdO
Today marks a great step forward with the first-ever #FDA approval of the subcutaneous formulation of #Leqembi (lecanemab), a major advancement ushering in the next gen of #Alzheimer’s care with combination therapy and precision medicine.
bit.ly/47Pga8Y
bit.ly/47Pga8Y
August 29, 2025 at 11:33 PM
Today marks a great step forward with the first-ever #FDA approval of the subcutaneous formulation of #Leqembi (lecanemab), a major advancement ushering in the next gen of #Alzheimer’s care with combination therapy and precision medicine.
bit.ly/47Pga8Y
bit.ly/47Pga8Y
Healthcare startups are turning to venture philanthropy to advance bold ideas amid a challenging funding environment. Karen Harris shares how the ADDF bridges the gap with investments and a willingness to support high-risk, early-stage science.
wewillcure.com/insights/inv...
wewillcure.com/insights/inv...
Is Venture Philanthropy Right for Your Startup? Here’s How to Tell
At a time when federal funding is shrinking, healthcare startups are finding critical support from mission-driven venture philanthropies like the ADDF and LLS willing to back early-stage, high-risk sc...
wewillcure.com
August 20, 2025 at 1:21 PM
Healthcare startups are turning to venture philanthropy to advance bold ideas amid a challenging funding environment. Karen Harris shares how the ADDF bridges the gap with investments and a willingness to support high-risk, early-stage science.
wewillcure.com/insights/inv...
wewillcure.com/insights/inv...